These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29288321)

  • 1. RASSF1A promoter methylation was associated with the development, progression and metastasis of cervical carcinoma: a meta-analysis with trial sequential analysis.
    Zheng F; Yu H
    Arch Gynecol Obstet; 2018 Feb; 297(2):467-477. PubMed ID: 29288321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias.
    Lai HC; Lin YW; Chang CC; Wang HC; Chu TW; Yu MH; Chu TY
    Gynecol Oncol; 2007 Mar; 104(3):629-35. PubMed ID: 17097722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between RASSF1A Promoter Hypermethylation and Oncogenic HPV Infection Status in Invasive Cervical Cancer: a Meta-analysis.
    Li JY; Huang T; Zhang C; Jiang DJ; Hong QX; Ji HH; Ye M; Duan SW
    Asian Pac J Cancer Prev; 2015; 16(14):5749-54. PubMed ID: 26320446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
    Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
    Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of RASSF1A in premalignant cervical lesions: clinical and prognostic significance.
    Mitra S; Mazumder Indra D; Basu PS; Mondal RK; Roy A; Roychoudhury S; Panda CK
    Mol Carcinog; 2012 Sep; 51(9):723-33. PubMed ID: 21809394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor lesions in cervical cancer.
    Rogeri CD; Silveira HCS; Causin RL; Villa LL; Stein MD; de Carvalho AC; Arantes LMRB; Scapulatempo-Neto C; Possati-Resende JC; Antoniazzi M; Longatto-Filho A; Fregnani JHTG
    Gynecol Oncol; 2018 Sep; 150(3):545-551. PubMed ID: 29960712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens.
    Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
    Gynecol Oncol; 2010 Jan; 116(1):99-104. PubMed ID: 19836067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III.
    Terra AP; Murta EF; Maluf PJ; Caballero OL; Brait M; Adad SJ
    Tumori; 2007; 93(6):572-9. PubMed ID: 18338492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens.
    Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Kweon SS; Fackler MJ; Sukumar S
    Virchows Arch; 2010 Jul; 457(1):35-42. PubMed ID: 20496080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia.
    Steenbergen RD; Kramer D; Braakhuis BJ; Stern PL; Verheijen RH; Meijer CJ; Snijders PJ
    J Natl Cancer Inst; 2004 Feb; 96(4):294-305. PubMed ID: 14970278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quantitative detection of APC/RASSF1A promoter methylation in the plasma of patients with cervical diseases].
    Wang H; Pan SY; Pang ZR; Wang F; Xu J; Chen D; Xie EF; Zhang LX; Gao L; Xu YQ; Jin B
    Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):929-34. PubMed ID: 24495688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Promoter methylation of DAPK1, RAR-β and MGMT in exfoliated cervical cytology and its clinical application].
    Zhong ZJ; Yang JX; Cao DY; Sun Y; Sun LL; Cheng XM; Chen J; Lang JH; Shen K
    Zhonghua Fu Chan Ke Za Zhi; 2012 Mar; 47(3):196-200. PubMed ID: 22781071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDH1 promoter methylation in patients with cervical carcinoma: a systematic meta-analysis with trial sequential analysis.
    Liu G
    Future Oncol; 2018 Jan; 14(1):51-63. PubMed ID: 29237293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of human papillomavirus 16 e6 gene expression and cervical intraepithelial neoplasia progression by methylation status.
    Hublarova P; Hrstka R; Rotterova P; Rotter L; Coupkova M; Badal V; Nenutil R; Vojtesek B
    Int J Gynecol Cancer; 2009 Apr; 19(3):321-5. PubMed ID: 19407553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer.
    Nye MD; Hoyo C; Huang Z; Vidal AC; Wang F; Overcash F; Smith JS; Vasquez B; Hernandez B; Swai B; Oneko O; Mlay P; Obure J; Gammon MD; Bartlett JA; Murphy SK
    PLoS One; 2013; 8(2):e56325. PubMed ID: 23418553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation of the RASSF1A gene promoter in Uigur women with cervical squamous cell carcinoma.
    Pan Z; Li J; Pan X; Chen S; Wang Z; Li F; Qu S; Shao R
    Tumori; 2009; 95(1):76-80. PubMed ID: 19366060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of detection of tumor suppressor genes aberrant methylation in cervical carcinoma tissue].
    Xu J; Wang HL; Lu GC; Wang ZJ; Lin X; Zhou HW
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):394-7. PubMed ID: 17697601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
    Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
    Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population.
    Neyaz MK; Kumar RS; Hussain S; Naqvi SH; Kohaar I; Thakur N; Kashyap V; Das BC; Husain SA; Bharadwaj M
    Biomarkers; 2008 Sep; 13(6):597-606. PubMed ID: 18608185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.
    De Strooper LMA; Berkhof J; Steenbergen RDM; Lissenberg-Witte BI; Snijders PJF; Meijer CJLM; Heideman DAM
    Int J Cancer; 2018 Sep; 143(6):1541-1548. PubMed ID: 29663363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.